Overview

Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee

Status:
Withdrawn
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of zoledronic acid in patients presenting with spontaneous osteonecrosis of the knee.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Treatments:
Diphosphonates
Zoledronic Acid